Q: What is Koselugo used for?

Koselugo is used to treat neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas .

Q: How does Koselugo work?

Targeting Cell Growth Koselugo is a type of medication called a kinase inhibitor. It works by blocking the activity of specific proteins known as MEK1 and MEK2. These proteins are part of a complex signaling chain in the body that controls how cells grow and divide. In individuals with neurofibromatosis type 1 (NF1), a genetic change causes this signaling chain to stay active more than it should. This constant signaling leads to the development of plexiform neurofibromas, which are tumors that grow along the nerves and can cause pain, weakness, or other physical complications. By interfering with the MEK proteins, Koselugo helps to: Block the signals that promote tumor cell growth. Prevent the tumors from getting larger. Shrink the size of the tumors in some cases. This targeted approach focuses on the specific biological pathway responsible for the tumor growth associated with NF1, rather than affecting all rapidly dividing cells in the body.

Q: What are the active ingredients in Koselugo?

The active ingredient in Koselugo is selumetinib .

Q: What are the side effects of Koselugo?

Common side effects of Koselugo may include: diarrhea nausea vomiting and others Always consult with a healthcare professional about potential side effects.

Q: What drug class is Koselugo?

Koselugo belongs to the MEK inhibitor drug class.

Q: What is the dosage of Koselugo and how do I take it?

How to Take Koselugo Koselugo comes as a capsule to be taken by mouth. It is usually taken twice a day. It is important to take this medication on an empty stomach to ensure it is absorbed correctly. You should not eat any food for at least two hours before taking a dose and for at least one hour after taking a dose. Swallow the capsules whole with a glass of water. Do not chew, crush, dissolve, or open the capsules. Try to take your doses at the same times every day to maintain a consistent level of medicine in your body. Missed Doses If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular schedule. Do not take two doses at the same time to make up for a missed one. General Guidance Your healthcare provider will determine how long you should continue treatment based on your response to the medication and any side effects you may experience. Do not change your dose or stop taking the medication without consulting your doctor. If you have trouble swallowing capsules whole, speak with your healthcare provider for further instructions.

Q: Is Koselugo safe during pregnancy and breastfeeding?

Pregnancy Koselugo may cause harm to a fetus when administered to a pregnant person. Before starting treatment, a pregnancy test is typically performed for individuals of reproductive potential to ensure they are not pregnant. Effective birth control should be used during treatment and for a period after the final dose: Females: Use effective contraception during treatment and for at least 1 week after the last dose. Males: Use effective contraception during treatment and for at least 1 week after the last dose if you have a female partner of reproductive potential. If pregnancy occurs during treatment, it is important to notify a healthcare provider immediately to discuss the potential risks to the fetus. Breastfeeding It is not known whether Koselugo passes into human breast milk. Due to the risk of serious side effects in a nursing infant, breastfeeding is not recommended during treatment and for 1 week following the final dose. Fertility Based on findings from animal studies, Koselugo may affect female fertility. The long-term impact on human fertility is not fully known. Individuals concerned about their ability to have children should discuss this with their healthcare provider before starting treatment.

Q: What is the FDA approval status of Koselugo?

FDA Approval History The U.S. Food and Drug Administration (FDA) first approved Koselugo in April 2020. This initial approval was for pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). In May 2024, the FDA expanded the approval to include adult patients with the same condition. Approved Indications Koselugo is indicated for the treatment of adult and pediatric patients (2 years of age and older) with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas. These are tumors that grow along the nerves and are considered inoperable when they cannot be completely removed without risking significant survival or causing major functional issues. Regulatory Designations During its development, Koselugo received several special regulatory designations from the FDA, including: Orphan Drug Designation: Granted to support the development of drugs for rare diseases. Breakthrough Therapy Designation: Intended to expedite the development and review of drugs for serious conditions where preliminary clinical evidence indicates substantial improvement over available therapies. Priority Review: Assigned to applications for drugs that would provide significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions. Safety Monitoring The FDA monitors the safety of Koselugo through ongoing surveillance and adverse event reporting systems. Healthcare providers and patients are encouraged to report side effects to the FDA MedWatch program. There is currently no Boxed Warning or Risk Evaluation and Mitigation Strategy (REMS) program required for this medication.

Question 1

What is Koselugo?

Accepted Answer

Koselugo is a type of medication known as a kinase inhibitor. It works by blocking the action of specific proteins in the body that signal cells to grow and multiply. By targeting these proteins, the medication helps to interfere with the development and expansion of certain tumor cells.

This medication is specifically classified as a MEK inhibitor. It is designed to slow the progression of tumors by disrupting the signaling pathways that allow them to grow and survive.

Question 2

What is Koselugo used for?

Accepted Answer

Koselugo is used to treat neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas.

Question 3

How does Koselugo work?

Accepted Answer

Targeting Cell Growth

Koselugo is a type of medication called a kinase inhibitor. It works by blocking the activity of specific proteins known as MEK1 and MEK2. These proteins are part of a complex signaling chain in the body that controls how cells grow and divide.

In individuals with neurofibromatosis type 1 (NF1), a genetic change causes this signaling chain to stay active more than it should. This constant signaling leads to the development of plexiform neurofibromas, which are tumors that grow along the nerves and can cause pain, weakness, or other physical complications.

By interfering with the MEK proteins, Koselugo helps to:

Block the signals that promote tumor cell growth.
Prevent the tumors from getting larger.
Shrink the size of the tumors in some cases.

This targeted approach focuses on the specific biological pathway responsible for the tumor growth associated with NF1, rather than affecting all rapidly dividing cells in the body.

Question 4

What are the active ingredients in Koselugo?

Accepted Answer

The active ingredient in Koselugo is selumetinib.

Question 5

What are the side effects of Koselugo?

Accepted Answer

Common side effects of Koselugo may include:

diarrhea
nausea
vomiting
and others

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Koselugo?

Accepted Answer

Koselugo belongs to the MEK inhibitor drug class.

Question 7

What is the dosage of Koselugo and how do I take it?

Accepted Answer

How to Take Koselugo

Koselugo comes as a capsule to be taken by mouth. It is usually taken twice a day. It is important to take this medication on an empty stomach to ensure it is absorbed correctly. You should not eat any food for at least two hours before taking a dose and for at least one hour after taking a dose.

Swallow the capsules whole with a glass of water.
Do not chew, crush, dissolve, or open the capsules.
Try to take your doses at the same times every day to maintain a consistent level of medicine in your body.

Missed Doses

If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular schedule. Do not take two doses at the same time to make up for a missed one.

General Guidance

Your healthcare provider will determine how long you should continue treatment based on your response to the medication and any side effects you may experience. Do not change your dose or stop taking the medication without consulting your doctor. If you have trouble swallowing capsules whole, speak with your healthcare provider for further instructions.

Question 8

Is Koselugo safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Koselugo may cause harm to a fetus when administered to a pregnant person. Before starting treatment, a pregnancy test is typically performed for individuals of reproductive potential to ensure they are not pregnant.

Effective birth control should be used during treatment and for a period after the final dose:

Females: Use effective contraception during treatment and for at least 1 week after the last dose.
Males: Use effective contraception during treatment and for at least 1 week after the last dose if you have a female partner of reproductive potential.

If pregnancy occurs during treatment, it is important to notify a healthcare provider immediately to discuss the potential risks to the fetus.

Breastfeeding

It is not known whether Koselugo passes into human breast milk. Due to the risk of serious side effects in a nursing infant, breastfeeding is not recommended during treatment and for 1 week following the final dose.

Fertility

Based on findings from animal studies, Koselugo may affect female fertility. The long-term impact on human fertility is not fully known. Individuals concerned about their ability to have children should discuss this with their healthcare provider before starting treatment.

Question 9

What forms and strengths does Koselugo come in?

Accepted Answer

Koselugo is supplied as a capsule for oral administration. The capsules are intended to be swallowed whole with water and should not be chewed, crushed, or opened before use.

Oral Capsule: This is the only available form for this medication.

Question 10

What is the FDA approval status of Koselugo?

Accepted Answer

FDA Approval History

The U.S. Food and Drug Administration (FDA) first approved Koselugo in April 2020. This initial approval was for pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). In May 2024, the FDA expanded the approval to include adult patients with the same condition.

Approved Indications

Koselugo is indicated for the treatment of adult and pediatric patients (2 years of age and older) with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas. These are tumors that grow along the nerves and are considered inoperable when they cannot be completely removed without risking significant survival or causing major functional issues.

Regulatory Designations

During its development, Koselugo received several special regulatory designations from the FDA, including:

Orphan Drug Designation: Granted to support the development of drugs for rare diseases.
Breakthrough Therapy Designation: Intended to expedite the development and review of drugs for serious conditions where preliminary clinical evidence indicates substantial improvement over available therapies.
Priority Review: Assigned to applications for drugs that would provide significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions.

Safety Monitoring

The FDA monitors the safety of Koselugo through ongoing surveillance and adverse event reporting systems. Healthcare providers and patients are encouraged to report side effects to the FDA MedWatch program. There is currently no Boxed Warning or Risk Evaluation and Mitigation Strategy (REMS) program required for this medication.

Question 11

What should I know about Koselugo and cost?

Accepted Answer

Insurance and Pharmacy Factors

The out-of-pocket cost for Koselugo is largely determined by your insurance plan's specific benefits. Most insurance providers require a prior authorization process before they will cover the medication. Additionally, because Koselugo is a specialty drug, it is often only available through specific specialty pharmacies rather than standard retail locations.

Generic Status

Koselugo is a brand-name medication containing the active ingredient selumetinib. There is currently no generic version available. Brand-name medications generally cost more than their generic counterparts.

Financial Assistance Programs

There may be options available to help manage the cost of treatment:

Manufacturer Support: The company that makes Koselugo may offer patient assistance programs or copay savings cards for those who meet certain eligibility requirements.
Non-profit Organizations: Some foundations provide financial aid to patients with rare diseases to help cover medication costs or insurance premiums.

Patients should consult with their healthcare provider or insurance company to understand the specific costs associated with their treatment plan.

Koselugo

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Koselugo

Hospitals.net Disclosure